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Abstract Purpose: The aim of this survey was to review the different stud- 
ies regarding the occurrence of second primary tumors (s PT) among survi- 
vors of retinoblastoma. Methods: Ovid (Medline, Current contents life, 
Psychlit, Embase) was searched for the years 1966 - 1995 using the mesh head- 
ings: ‘retinoblastoma’, ‘second primary neoplasms’, and ‘multiple primary 
neoplasms’. The inclusion criteria were: the study should involve 50 patients 
or more and should not be limited to one specific SPT. A checklist with crite- 
ria regarding the study design and the results was applied to each study. Re- 
sults: Eleven studies were identified which met the inclusion criteria. Thirty- 
five different types of S P T  (Ntotal=z43) were reported. Most of them were os- 
teosarcomas (37.0%), followed by melanomas (7.4%), soft-tissue sarcomas 
(6.9%), brain tumors (4.5%), fibrosarcomas (3.3%), chondrosarcomas 
(3.3%), and sarcomas (3.3%). Less frequently reported were leukemias 
(2.4%), sebaceous cell carcinomas (1.6%), and non-Hodgkin lymphomas 
(1.6). Pineoblastoma, which in fact is a trilateral retinoblastoma and not an 
S P T ,  was found in 2.4%. Despite the differences, all 11 studies showed a high- 
er incidence of S P T  compared to the general population. Only 4 studies were 
judged to be free from selection bias, reporting a cumulative incidence of S P  T 
of 8.4% 18 years after diagnosis, 15.7% at the age of 20 years, 19% at the age of 
35 years, and a relative risk of 15.4 for s P T, respectively. Conclusion: s P T is a 
serious problem for the survivors of hereditary retinoblastoma and its impor- 
tance shoud be recognized in (genetic) counseling of patients. 
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Introduction Retinoblastoma is a malignant tumor of the retina in chil- 
dren. It can occur either unilaterally of bilaterally and may be familial or 
sporadic. Patients in whom the tumor is known to be familial and those with 
bilateral retinoblastoma have the hereditary form (30 - 40%). Patients with 
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unilateral retinoblastoma without a family history mostly have the nonhere- 
ditary form (60-70%).’ In the hereditary form of retinoblastoma, a mutation 
of the RBI gene on chromosome 13914 is present in all cells of the body, 
whereas in the nonhereditary form this mutation is only seen in the tumor 
cells of the retina.2 Retinoblastoma is curable in most  patient^.^-^ However, 
hereditary retinoblastoma patients have a high risk of developing second pri- 
mary tumor (SPT) in their childhood or adolescence. A high risk for S P T  is 
also reported for adult hereditary retinoblastoma ~atients.6’~ This high risk 
for S P T  in hereditary retinoblastoma patients is probably due to the germline 
mutation of the retinoblastoma gene (RBI) in all body cells. Consequently, the 
first step in the oncogenesis pathway is already present in all cells.’ Numerous 
articles have been published regarding the occurrence of s P T  in retinoblasto- 
ma patients since the first publication by Reese et al.9 in 1949. These studies 
differ substantially in design and size, and partly for this reason there is a 
considerable variety in the reported incidence of S P  T. 
In (genetic) counseling of retinoblastoma patients or their parents, it is dif 
ficult to provide adequate information regarding the incidence of s P T  based 
on the literature. Therefore, the aim of this review is to evaluate critically the 
different articles regarding s P T among survivors of retinoblastoma. 
Methods A search was done in Ovid (Medline, Current contents life, 
Psychlit, Embase) for the years 1966-1995 using the mesh headings: ‘retino- 
blastoma’, ’second primary neoplasms’, and ‘multiple primary neoplasms’. 
The inclusion criteria were: the study should involve 50 patients or more and 
should not be limited to one specific SPT. Consequently, case reports and 
small case series were excluded. The references of the articles identified 
were checked. A checklist with criteria regarding the study design and the 
results was applied to each study. With respect to study design, the following 
issues were checked: origin of the patient group (clinic(s) and country), 
whether it was population-based or not, the primary retinoblastoma treat- 
ment, the number of patients included, whether it concerned a population 
with different types of retinoblastoma (percentage of the retinoblastoma 
types in terms of laterality or heredity), the follow-up period, the number of 
patients with completed follow-up, and the statistical method. Data extrac- 
tion regarding the results concerned the cumulative incidence of SPT, death 
due to SPT, and the number of different types of SPT.  
Results 
RESULT OF T H E  SEARCH FOR ARTICLES Two hundred and six articles 
were identified in Ovid under the mesh headings: ‘retinoblastoma’, ‘second 
primary neoplasms’, and ‘multiple primary neoplasms’. Fifteen articles fi-11- 
filled the inclusion ~riteria.6”“~~ However, seven of the 15 a r t i~ les~~”-’~”~~’’  
dealt with the same patient series: from these we selected the most complete 
versions for our One review article was found regarding S P T  and 
retinobla~toma.2~ One hundred and ninety articles were excluded: these arti- 
cles consisted of case reports, studies with less than 50 patients, and studies 
limited to one specific SPT. Furthermore, these 190 articles either dealt with 
SPT among relatives of retinoblastoma patients or reported not on the cumu- 
lative incidence of SPT, but on other aspects such as therapy of SPT, SPT in 
general, retinoblastoma in general, and detection of s PT. 
28 A. C. Moll et al. 
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Author Clinic Period n Type F o N o ~ ~ - u p  SP T Stat 
(country) RB 
Pat(%) Mean period n Cum Inc Death (%) 
Jensen & Miller" 6 centers (USA) 1914- 1969 
DeSutter et al.I6 Gent (Belgium) 1950- 1984 
Essen (Germany) 1960- 1984 
Lueder et aI.l4 IowaCity (USA) 1924-1985 
DerKinderen et al.'* Populat (Holland) 1945- 1970 
Winther et al." Populat (Denmark) 1943- 1984 
Smith et a1.2' Stanford (USA)  1954-1986 
Desjardin et Paris (France) 1922 - I 965 
Minoda et a1.23 Populat (Japan) 1975-1982 
Eng et aL6 NYiEoston (USA)  1914- 1984 
Draper et aI.l5 Centers (u K) 1962- I977 
Roarty et al.I9 AFIP (USA)  1922 - I973 
I 623 
I I 0  
515 
50 
882 
141 
215 
I75 
53 
80 
409 
I 603 
? 
4o%bil 
66%bil 
I oo%her 
44%her 
I oo%her 
I oo%bil 
34%her 
79%her 
I oo%bil 
ioo%her 
57Ynbil 
? ? 
65 ? 
? ? 
? ? 
I00 ? 
I00 25Y 
? 7.2Y 
87 24Y 
92 I IY  
30 3IY 
? ? 
91 '7Y 
? 
KM 
KM 
K M  
Act 
KM 
LT 
R R  
Act 
? 
RR, 
KM 
n, number of patients; AFIP, Armed Forces Institute of Pathology; NY, New York; y, years; SPT, second primary tumor; RB, retinoblastoma; bil, 
bilateral; her, hereditary; RR, relative risk in comparison to the population, populat, population-based; KM, Kaplan-Meier; LT, life table; Act, ac- 
tuarial; pat, patients, Cum Inc, cumulative incidence for the total period at issue; death, case fatality rate of SPT; stat, statistical method; ?,was not 
stated in the publication and could also not be inferred or calculated. 
S T U D Y  D E S I G N  O F  T H E  I I S T U D I E S  Table I shows an overview of the 11 
we included that reported on the occurrence of s P T in 
retinoblastoma patients. These I I studies differed substantially in design and 
population size. All 11 studies dealt with a historical cohort.The cohorts were 
identified within a single i n ~ t i t u t i o n , ' ~ ' ~ ~ ~ ~ ~ , ~ ~  in . multiple ~en te r s ,6"~"~"~  or in 
population-based r e g i s t r i e ~ . ' ~ . ~ ~ , ~ ~  The reported periods occurred between 
1914 and 1990.  Two studies were restricted to bilateral'9,22 and four to heredi- 
tary retinoblastoma, i.e. bilateral or unilateral with a positive family his- 
tory. 14,18,22,23 One study was unclear with regard to the laterality." The other 
studies included information regarding different mixed bilateral/ unilat- 
era16,14316,19,22 or hereditary/ n~nhereditary'~"~"~'~~,~'~~~ retinoblastoma pa- 
tient series. The proportion of patients with a complete follow-up was 
indicated explicitly in seven studies6,'5'16,18,20-22 and the mean follow-up per- 
iod ranged from 7.2 to 31 years. Only the median was given in three stud- 
ies.6319321 In one series,6 the endpoint of follow-up was mortality due to S P T ,  
in the other series10,14-16,18-23 the endpoint of follow-up was the diagnosis of 
SPT.  The case fatality rate is given in seven series.6,'4,'6,18,21-23 In one series,6 
the cumulative death due to S P T  in hereditary retinoblastoma patients is 
given. Different statistical methods were used: actuarial methods,15321 Kap- 
lan-Meier,143163's and life-table analysis" are difficult to compare with rela- 
tive risk.6320 
One studyI4 also included pineoblastoma (trilateral retinoblastoma) as an 
S P T  (n=3). Another study" included three brain tumors, one of which was 
probably a pineoblastoma, as suggested by the authors. The other studies 
did not regard pineoblastoma as being an s P T. 
T A B L E  I .  Overview of the literature 
regarding second Primary tumors 
among survivors Of retinoblastoma. 
studies6, 10,14-16,18-23 
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C O N T E N T S  OF T H E  11 S T U D I E S  W I T H  R E L A T I O N  T O  S T P  Jensenetal." 
reported that radiotherapy was associated with an increased risk of osteo- 
sarcomas, soft-tissue neoplasms, or carcinomas of the skin (n=30 radio- 
induced SPT), but they also reported 11 S P T  which were considered not to be 
radiogenic. 
The studies in Gent (Belgium) and Essen (Germany) by De Sutter et a1.16 
showed a cumulative incidence of second primary tumors ranging from 10% 
to 30% in a retinoblastoma population (40% had bilateral retinoblastoma), 
using a life-table analysis. They concluded that the incidence of S P T  was in- 
dependent of radiotherapy. In Gent, only six patients were treated with che- 
motherapy, so that the authors were not able to determine its influence on 
SPT. In Essen, chemotherapy did not seem to influence the risk of SPT.  
In 50 hereditary retinoblastoma patients, Lueder et al.I4 found a cumula- 
tive incidence of S P T  of 6%, 14%, and 14% after 10,20, and 30 years, respec- 
tively. Pineoblastoma was the probable cause of death in three of the five 
patients in this seriesI4 who died of SPT.  They did not find a (osteo)sarcoma. 
Draper et al? found a cumulative incidence of 8.4% for all S P T  in heredi- 
tary retinoblastoma patients 18 years after initial treatment; this figure was 
6.0% for osteosarcoma only. Their results also suggested that the use of cyclo- 
phosphamide might increase the risk of s P T  in hereditary retinoblastoma 
patients. The six pineoblastomas were not considered as SPT, but were re- 
ported separately in an article on ectopic intracranial retinobla~toma.~~ 
These authors15 also mentioned strong evidence for an association between 
retinoblastoma and malignant melanoma. 
The Dutch population-based study" showed a cumulative incidence of 
S P T  of 19% in hereditary retinoblastoma patients at the age of 35 years. 
Roarty et al.19 reported a cumulative incidence of S P T  in patients with bi- 
lateral retinoblastoma of 4.4% ten years after diagnosis, 18.3% after 20 years, 
and 26.1% after 30 years, using the life-table method. They concluded that the 
cumulative incidence of SPT was higher (although not significantly) in pa- 
tients who received radiation therapy (the cumulative incidence of s P T  was 
35.1% after 30 years). 
A population-based study in Denmark by Winther et a1.20 found three S P  T 
in 175 retinoblastoma patients (34% had hereditary retinoblastoma) and 
compared this risk with the risk in the general population. They reported a 
relative risk for SPT of 4 . 2  for all retinoblastoma patients, 15.4 for hereditary 
and 1.7 for nonhereditary retinoblastoma patients. These results, however, 
were based on one reported osteosarcoma, one Ewing sarcoma, and one ana- 
plastic tumor only. One pineoblastoma was also found, but it was not incor- 
porated into the study results. 
Smith et aL2' described the incidence O f  S P T  among 53 retinoblastoma pa- 
tients (79% had the hereditary form) seen in Stanford. Fifty of these 53 infants 
received irradiation, and eight patients of this subgroup developed 11 SPT. 
The actuarial incidence of S P T  was 6% ten years after diagnosis, 19% after 
20 years, and 38% after 30 years. They reported one pineoblastoma, but ex- 
cluded this tumor from the analysis. 
was able to follow up 24 of the 80 bilateral retinoblasto- 
ma patients in Paris for more than 30 years and found nine SPT, six of which 
were potentially radiation-induced. They calculated a percentage of s P T be- 
tween 18% and 68%, depending on the occurrence of S P T  in the 24 patients 
lost to follow-up (32 deceased due to retinoblastoma). 
Desjardin et 
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The Japanese population-based found a cumulative incidence 
among the 409 hereditary cases of 0% at the age of 5 years, 4.8% at 10 years, 
and 15.7% at 20 years. They also reported two unilateral nonfamilial cases 
with SPT.  
The large study by Eng et a1.6 in 1603 retinoblastoma patients with a follow- 
up of 91% of the patients showed 96 deaths from S P T  (relative risk of 30). With 
respect to the 919 bilateral retinoblastoma patients, the relative risk for S P T  
was 60 in comparison with that of the general population. After a 40-year 
follow-up, the cumulative mortality for all S P T  combined was 26.0% for the 
bilateral group and 1.5% for the unilateral group in comparison with the gen- 
eral population. 
D I F F E R E N T  T Y P E S  O F  S P T  I N  P E R C E N T A G E S  The 11 reviewed arti- 
reported a total of 243 S P T  divided into 35 different types. 
Most of them were osteosarcomas (37.0%), followed by melanomas (7.4%). 
soft-tissue sarcomas (6.9%), brain tumors (4.5%), fibrosarcomas (3.3%), 
chondrosarcomas (3.3%), and sarcomas (3.3%). Less frequently reported 
were leukemias (2.4%), sebaceous cell carcinoma (1.6%), and non-Hodgkin 
lymphomas (1.6%). Ten different S P  T types (squamous cell carcinoma, rhab- 
domyosarcoma, fibrous histiocytoma, Ewing sarcoma, liposarcoma, glio- 
blastoma, anaplastic cell carcinoma, transitional cell carcinoma, mening- 
ioma, astrocytoma) were mentioned two or three times only. Fifteen different 
s P T types were found only once. A high number of s P T types were unknown 
(9.8%). Twice, a metastasis was qualified as SPT.  Pineoblastomas, in fact a 
trilateral retinoblastoma and not an SPT,  was found in 2.4%. 
cles6, 10,14-16,18-23 
Discussion 
S T U D Y  D E S I G N  OF T H E  11 S T U D I E S  Only 11 a r t i ~ l e s ~ ” ’ ” ~ ~ ’ ~ ” * - ~ ~  on reti  
noblastoma and S P T  fulfilled the inclusion criteria. The design of these stud- 
ies, especially of those conducted in the past, was not very sophisticated. In 
the older studies, patients were drawn from the registries of one of a few de- 
partments of ophthalmology specializing in retinoblastoma, which probably 
led to an overrepresentation of complex patients. Difficult patients (mostly 
with hereditary retinoblastoma), possibly with a greater risk for S P T  (due to 
the R B  I mutation and/or excessive radiation therapy or chemotherapy), 
therefore, were more likely to be included in these studies, which may have 
caused a higher cumulative incidence of s P T. Population-based studies have 
the advantage of avoiding this type of selection bias. Three s t ~ d i e s ’ * , ~ ~ , ~ ~  were 
nationwide and free of this kind of selection bias. 
Documentation of the follow-up period varied from not i n d i ~ a t e d , ’ ~ , ’ ~ , ~ ~ , ~ ~  
to incomplete,6”6*20-22 to The reasons for loss to follow-up were 
not given. An incomplete follow-up of the series may influence the cumulative 
incidence O f  S P  T. The Japanese population-based covered the period 
1975-1982 with a relatively short follow-up to 1990. Therefore, S P T  such as 
melanomas, which occur in later life, were probably not found. Some studies 
did not clearly distinguish a metastasis from an S P T , ~ ~ , ~ ’  which could also 
lead to an overestimation of the cumulative incidence of SPT.  Eng et a1.6 re- 
ported nine brain tumors, which were not specified further: possibly the brain 
tumors were pineoblastomas or late metastases from retinoblastoma. An- 
other problem of this study was that the authors only reported on deaths 
Review retinoblastoma and secondprimary tumors 31 
O
ph
th
al
m
ic
 G
en
et
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
V
rije
 U
niv
ers
ite
it A
ms
ter
da
m 
on
 08
/19
/11
Fo
r p
er
so
na
l u
se
 o
nl
y.
due to s P T. Therefore, they probably missed some nonfatal s P T  and it is dig 
ficult to compare their results with others. Only the study of Winther et a1." 
presented relative risks in comparison with the general population. Despite 
the differences, all 11 studies showed an increased number of S P T  compared 
with the general population. Four of the 11 studies were judged free from 
selection bias, reporting cumulative incidences of S P T  of 8.4% 18 years15 
after diagnosis, 15.7% at the age of 20 19% at the age of 35 years18 
and a relative risk of 15.4 for S P T ~  in comparison with the general popula- 
tion, respectively. 
HEREDITARY VERSUS NONHEREDITARY RETINOBLASTOMA A N D  
s P T It seems clear from the data reported that the high risk for s P T is vir- 
tually confined to those with the hereditary form of retinoblastoma. As men- 
tioned in the introduction section, the high risk for S P T  in hereditary 
retinoblastoma patients is probably due to the germline mutation of the R B  I 
gene in all body cells. Consequently, the first step in the oncogenesis pathway 
is already present in all cells.8 Eng et a1.6 reported in their series five S P  T in 684 
children with unilateral retinoblastoma; the overall risk was significant 
(RR=3.1;  95% CI= 1.0-7.3). However, as they discussed, the increased risk 
was not entirely surprising, since a proportion of the patients with unilateral 
retinoblastoma could have in fact hereditary retinoblastoma, which placed 
them at a higher risk. The two unilateral nonfamilial retinoblastoma pa- 
tients with SPT mentioned in the Japanese studyz3 could also be hereditary 
cases with unilateral occurrence like other cases reported by Abramson et 
al." and Hausmann and Stefani21 
D I F F E R E N T  TYPES OF S P T  All in all, 35 different S P T  types were reported 
in the 11 studies. As was expected, most of the S P T  types were osteosarcomas 
and soft-tissue sarcomas. Hereditary retinoblastoma patients harbor the so- 
matic mutation in the R B  I gene. This mutation also appears to play a patho- 
genetic role in a substantial proportion of osteosarcomas and soft-tissue 
 sarcoma^.^^-^^ Another important finding is the high incidence of malignant 
melanomas (7.4%) which do not appear to harbor R B  I mutations.27 In an 
overview of the literature regarding melanoma and retinoblastoma, Traboul- 
si et al.30 reported that cutaneous malignant melanoma accounts for about 
7% (range 4.2%- 14.3%) of SPT. Pineoblastomas, trilateral retinoblastomas 
of the pineal gland,31,3z do not meet the definition of SPT,  because pineoblas- 
tomas cannot be distinguished histologically from primary tumor retinoblas- 
tomas. Despite this, two studies regarded pineoblastoma as an S P  T . ~ ~ ~ ~ ~  Some 
authors only mentioned the finding of a pineoblastoma in their s t ~ d y . ' ~ ~ ~ ~ , ~ '  A 
valid cumulative incidence of pineoblastoma has not yet been reported in the 
literature. Holladay et al.33 reported that 68% of the pineoblastoma patients 
had the familial hereditary form of retinoblastoma. 
R E  v I E  w Mitchellz4 gave a critical review of the literature of retinoblastoma 
and S P  T, but discussed fewer patient series. He also concluded that the overall 
incidence of S P T  is difficult to assess, because of the different methods and 
study groups, but that it is probably closer to 15% than to the 68% proposed 
by Abramson et ai.l3 
32 A. C. Moll et al. 
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C O N C L U S I O N  S P T  is a serious problem for the survivors ofhereditary reti- 
noblastoma and its importance should be recognized in (genetic) counseling 
of retinoblastoma patients. 
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